THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Rajagopal Ramesh to Apoptosis

This is a "connection" page, showing publications Rajagopal Ramesh has written about Apoptosis.
Connection Strength

2.205
  1. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget. 2015 Jun 30; 6(18):16271-86.
    View in: PubMed
    Score: 0.389
  2. EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS One. 2011; 6(11):e25507.
    View in: PubMed
    Score: 0.302
  3. Vitamin E succinate in combination with mda-7 results in enhanced human ovarian tumor cell killing through modulation of extrinsic and intrinsic apoptotic pathways. Cancer Lett. 2007 Sep 08; 254(2):217-26.
    View in: PubMed
    Score: 0.220
  4. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene. Cancer Gene Ther. 2005 Mar; 12(3):238-47.
    View in: PubMed
    Score: 0.190
  5. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb; 4(2):291-304.
    View in: PubMed
    Score: 0.189
  6. Interleukin (IL)-24: Reconfiguring the Tumor Microenvironment for Eliciting Antitumor Response. Adv Exp Med Biol. 2021; 1290:99-110.
    View in: PubMed
    Score: 0.142
  7. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
    View in: PubMed
    Score: 0.115
  8. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine. 2014; 9:3825-39.
    View in: PubMed
    Score: 0.091
  9. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer. 2007 Feb 02; 6:11.
    View in: PubMed
    Score: 0.054
  10. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007 Feb; 15(2):287-94.
    View in: PubMed
    Score: 0.054
  11. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res. 2005 Apr 15; 65(8):3017-24.
    View in: PubMed
    Score: 0.048
  12. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004 Dec; 10(6):1085-95.
    View in: PubMed
    Score: 0.047
  13. Adenovirus-mediated PTEN treatment combined with caffeine produces a synergistic therapeutic effect in colorectal cancer cells. Cancer Gene Ther. 2003 Nov; 10(11):803-13.
    View in: PubMed
    Score: 0.043
  14. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S23-37.
    View in: PubMed
    Score: 0.042
  15. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002 Nov; 1(13):1201-9.
    View in: PubMed
    Score: 0.040
  16. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002 Aug; 8(8):451-61.
    View in: PubMed
    Score: 0.040
  17. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 2002 Jul 04; 21(29):4558-66.
    View in: PubMed
    Score: 0.040
  18. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017 08 30; 7(1):9694.
    View in: PubMed
    Score: 0.028
  19. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016 10 04; 7(40):64820-64835.
    View in: PubMed
    Score: 0.027
  20. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
    View in: PubMed
    Score: 0.020
  21. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol. 2007 Nov; 31(5):985-1007.
    View in: PubMed
    Score: 0.014
  22. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15.
    View in: PubMed
    Score: 0.013
  23. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther. 2005 May; 11(5):724-33.
    View in: PubMed
    Score: 0.012
  24. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan; 11(1):160-72.
    View in: PubMed
    Score: 0.012
  25. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun; 9(6):818-28.
    View in: PubMed
    Score: 0.011
  26. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther. 2004 Mar; 9(3):355-67.
    View in: PubMed
    Score: 0.011
  27. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002 Sep; 8(9):2963-9.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES